Liberum Capital reissued their hold rating on shares of AstraZeneca plc (LON:AZN) in a report released on Tuesday. The brokerage currently has a GBX 5,200 ($67.88) price target on the biopharmaceutical company’s stock.
A number of other equities analysts also recently issued reports on AZN. Jefferies Group restated a hold rating on shares of AstraZeneca plc in a research report on Monday, June 6th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Monday, June 6th. Deutsche Bank AG restated a buy rating on shares of AstraZeneca plc in a research report on Tuesday, June 7th. JPMorgan Chase & Co. set a GBX 3,900 ($50.91) price objective on AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 7th. Finally, Berenberg Bank restated a buy rating and set a GBX 4,950 ($64.61) price objective on shares of AstraZeneca plc in a research report on Thursday, June 9th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) opened at 5092.5127 on Tuesday. The stock has a 50 day moving average price of GBX 5,005.11 and a 200 day moving average price of GBX 4,435.88. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm’s market cap is GBX 64.42 billion.
The firm also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.